Saturday, February 9, 2013

More Hyperinsulinemia, Insulin-Suppressive Drugs & Obesity (and Lustig)

Building on my last post on this topic ...

So far I've spent most of the blogging on a study comparing 3 doses of octreotide, an insulin suppressing drug, vs. placebo in a subset of obese people pre-tested and determined to be insulin hypersecreters as defined by a corrected ratio for insulin to glucose levels.  This post will focus more on two other studies using this drug, perhaps just the first ... let's see how long this gets ;-)    I think it will be easiest to number the 3 studies, all bearing Lustig's name:
I've already discussed the rather unimpressive performance of octreotide in Study 3.  While the highest dose group had the highest "response" rate (20.5% losing ≥5% initial weight), the rates were similar between the placebo group (11.4%) compared to the 40mg octreotide group (12.5%), which is important as this is the dose used in Studies 1&2.   Additionally, mean losses for the entire 40 & 60 mg groups were less than 2%, and even the most promising responders, Caucasian hypersecreters with above median CIR, only lost an average of less than 4% over 6 months.
Read more »

No comments:

Post a Comment